Alerts will be sent to your verified email
Verify EmailMAHAREM
|
IndoAmerican Advance
|
Accretion Pharma.
|
Parnax Lab
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
0.31 % | 35.81 % | 11.65 % |
|
5yr average Equity Multiplier
|
1.07 | 3.8 | 2.74 |
|
5yr Average Asset Turnover Ratio
|
0.15 | 0.96 | 1.01 |
|
5yr Avg Net Profit Margin
|
-36.65 % | 11.51 % | 4.21 % |
|
Price to Book
|
n/a | 0.0 | 1.77 |
|
P/E
|
n/a | 17.9 | 14.27 |
|
5yr Avg Cash Conversion Cycle
|
0.0 | 102.38 Days | 30.1 Days |
|
Inventory Days
|
0.0 | 253.65 Days | 45.64 Days |
|
Days Receivable
|
0.0 | 55.55 Days | 61.56 Days |
|
Days Payable
|
167.71 Days | 160.55 Days | 72.37 Days |
|
5yr Average Interest Coverage Ratio
|
-55.68 | 6.89 | 2.99 |
|
5yr Avg ROCE
|
-12.15 % | 43.29 % | 17.86 % |
|
5yr Avg Operating Profit Margin
|
-72.03 % | 19.95 % | 13.13 % |
|
5 yr average Debt to Equity
|
0.0 | 1.69 | 1.12 |
|
5yr CAGR Net Profit
|
n/a | 143.08 % | n/a |
|
5yr Average Return on Assets
|
-11.02 % | 11.24 % | 4.42 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
0.97 % | 73.52 % | 72.3 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 9.41 % |
|
Change in Promoter Holding (3 Yrs)
|
-17.4 % | 0.01 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
IndoAmerican Advance
|
Accretion Pharma.
|
Parnax Lab
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|